Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments." Preservation of ejaculatory function is a top ...

For years, there have been limited advancements in the treatment of early-stage bladder cancer like non-muscle invasive bladder cancer (NMIBC)—cancer that has not reached the muscle wall of the ...

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

The QUILT-3.032 trial showed a 71% complete response rate in patients with BCG-unresponsive bladder carcinoma in situ treated with NAI. NAI treatment demonstrated a cystectomy-free rate of 84% at 36 ...

CVAC 2.0 showed a median stone clearance of 96.44% for kidney stones under 2 cm. No correlation was found between stone clearance and stone location, Hounsfield units, prestented status, or stone ...

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical ...

Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies. Welcome back to Pearls & Perspectives, with Amy Pearlman, MD! In ...

Real-world data on Aquablation for benign prostatic hyperplasia (BPH) is largely comparable to what was seen in the pivotal WATER I and WATER II clinical trials, according to data presented at the ...

The ProVee Urethral Expander System met all safety and effectiveness endpoints in a phase 3 study for BPH, showing significant symptom improvement. No device- or procedure-related serious adverse ...

Welcome back to Pearls & Perspectives, with Amy Pearlman, MD! In this 2-part episode of Pearls and Perspectives fromthe American Urological Association's (AUA) 2025 Annual Meeting in Las Vegas, NV, ...

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial. Data from the phase 3 ENLIGHTED trial (NCT04620239) showed preliminary safety and efficacy with padeliporfin ...